58077-68-2 Usage
Description
4-(4-Methyl-1-piperazinyl)butanoic Acid, also known as Gabapentin, is a chemical compound with the molecular formula C11H22N2O2. It is a medication belonging to the class of anticonvulsant drugs, which works by influencing the chemicals and nerves in the body that are involved in seizures and the symptoms of neuropathic pain.
Uses
Used in Pharmaceutical Industry:
4-(4-Methyl-1-piperazinyl)butanoic Acid is used as an anticonvulsant medication for the treatment of epilepsy, neuropathic pain, and restless leg syndrome. It modulates the activity of certain neurotransmitters and nerve receptors, providing relief from seizures and neuropathic pain symptoms.
4-(4-Methyl-1-piperazinyl)butanoic Acid is used as a therapeutic agent for the management of various neurological conditions, including epilepsy, neuropathic pain, and restless leg syndrome. Its mechanism of action involves affecting the chemicals and nerves in the body that are involved in these conditions, leading to a reduction in their severity and frequency.
It is typically prescribed in tablet or capsule form and is taken orally. However, it is crucial to follow the directions of a healthcare professional when using this medication, as it can have potential side effects and interactions with other drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 58077-68-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,0,7 and 7 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 58077-68:
(7*5)+(6*8)+(5*0)+(4*7)+(3*7)+(2*6)+(1*8)=152
152 % 10 = 2
So 58077-68-2 is a valid CAS Registry Number.
58077-68-2Relevant articles and documents
Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy,2-naphthyl)propionic acid (naproxen) for topical drug delivery
Rautio, Jarkko,Nevalainen, Tapio,Taipale, Hannu,Veps?l?inen, Jouko,Gynther, Jukka,Laine, Krista,J?rvinen, Tomi
, p. 1489 - 1494 (2007/10/03)
Various novel morpholinyl- (3a,b) and methylpiperazinylacyloxyalkyl (3c- f) esters of 2-(6-methoxy-2-naphthyl)propionic acid were synthesized and evaluated in vitro for topical drug delivery as potential prodrugs of naproxen (1). Compounds 3a-f were prepared by coupling the corresponding naproxen hydroxyalkyl ester with the morpholinyl- or (4-methyl-1- piperazinyl)acyl acid in the presence of dicyclohexylcarbodiimide (DCC) and 4-(dimethylamino)-pyridine (DMAP) and quantitatively hydrolyzed (t(1/2) = 1- 26 min) to naproxen in human serum. Compounds 3c-f showed higher aqueous solubility and similar lipophilicity, determined by their octanol-buffer partition coefficients (log P(app)), at pH 5.0 when compared to naproxen. At pH 7.4 they were significantly more lipophilic than naproxen. The best prodrug 3c led to a 4-and 1.5-fold enhancement of skin permeation when compared to naproxen at pH 7.4 and 5.0, respectively. The present study indicates using a methylpiperazinyl group yields prodrugs that are partially un-ionized under neutral and slightly acidic conditions, and thus, a desirable combination is achieved in terms of aqueous solubility and lipophilicity. Moreover, the resulting combination of biphasic solubility and fast enzymatic hydrolysis of the methylpiperazinylacyloxyalkyl derivatives gave improved topical delivery of naproxen.